A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
: Objective. To identify a screening model that predicts high risk of future type 2 diabetes and is useful in clinical practice. Design and methods. Incident case‐referent study nested within a population‐based health survey. We compared screening models with three risk criteria and calculated sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and attributable proportion. We used fasting plasma glucose (FPG) alone or with an oral glucose tolerance test (OGTT), glycosylated haemoglobin A (HbA1c) (normal range 3.6–5.3%), body mass index (BMI), triglycerides and family history of diabetes (FHD). Setting. Participants in a health survey at all primary care centres (n = 33 336) and subjects with diagnosed type 2 diabetes in primary and hospital care (n = 6088) in Umeå during 1989–2001. Subjects. Each of the 164 subjects who developed clinically diagnosed type 2 diabetes (median time to diagnosis of 5.4 years) and 304 sex‐ and age‐matched referents without diabetes diagnosis. Results. Screening models with at least one criterion present had sensitivities of 0.90–0.96, specificities of 0.43–0.57 and PPVs of 8–9%. Combinations of the criteria, FPG ≥ 6.1 mmol L−1 (capillary plasma), HbA1c ≥ 4.7% and BMI ≥ 27 in men and BMI ≥ 30 in women, had sensitivities, specificities and PPVs of 0.66%, 0.93% and 32%, and 0.52%, 0.97% and 46% respectively. Using FHD as one of three risk criteria showed comparable results. Addition of triglycerides or OGTT did not improve the prediction. Conclusions. The combination of HbA1c, FPG and BMI are effective in screening for individuals at risk of future clinical diagnosis of type 2 diabetes. OGTT or FHD is not necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Self-citationWeight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000380842.14048.7e · Cited by 1,600
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Confidence interval estimation of interaction
Hosmer, D. W., & Lemeshow, S. (1992) · Epidemiology · doi:10.1097/00001648-199209000-00012 · Cited by 1,239
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
The DECODE Study Group, & on behalf of the European Diabetes Epidemiology Group (2003) · Diabetes Care · doi:10.2337/diacare.26.3.688 · Cited by 516
Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.
Rohlfing, C. L., Little, R. R., Wiedmeyer, H. M., England, J. D., Madsen, R., Harris, M. I., Flegal, K. M., Eberhardt, M. S., & Goldstein, D. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.187 · Cited by 370
The nested case-control study in cardiology
Essebag, V., Genest, J., Suissa, S., & Pilote, L. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00512-x · Cited by 173
Cited by
A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes
Paulweber, B., Valensi, P., Lindström, J., Lalic, N., Greaves, C., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., et al. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1240928 · Cited by 469
A1C level and future risk of diabetes: a systematic review
Zhang, X., Gregg, E. W., Williamson, D. F., Barker, L. E., Thomas, W., Bullard, K. M., Imperatore, G., Williams, D. E., & Albright, A. L. (2010) · Diabetes Care · doi:10.2337/dc09-1939 · Cited by 422
“A1C values in three studies (11,24,25) were standardized by the NGSP, one (22) by the International Federation of Clinical Chemists, and another (21) by the Swedish MonoS Standard.”
MethodJagannathan-Bogdan, M., McDonnell, M. E., Shin, H., Rehman, Q., Hasturk, H., Apovian, C. M., & Nikolajczyk, B. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002615 · Cited by 417
The Västerbotten Intervention Programme: background, design and implications
Norberg, M., Wall, S., Boman, K., & Weinehall, L. (2010) · Global Health Action · doi:10.3402/gha.v3i0.4643 · Cited by 373
Self-citationSchulze, M. B., Hoffmann, K., Boeing, H., Linseisen, J., Rohrmann, S., Möhlig, M., Pfeiffer, A. F. H., Spranger, J., Thamer, C., Häring, H.-U., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2089 · Cited by 372
Risk assessment tools for identifying individuals at risk of developing type 2 diabetes
Buijsse, B., Simmons, R. K., Griffin, S. J., & Schulze, M. B. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxq019 · Cited by 297
“(41, 111) frequently involves prescreening, which hampers extrapolation to general populations.”
BackgroundDevelopment of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
Prediction of Type 2 Diabetes Based on Machine Learning Algorithm
Deberneh, H. M., & Kim, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063317 · Cited by 261
Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
Sattar, N., Wannamethee, S. G., & Forouhi, N. G. (2008) · Diabetologia · doi:10.1007/s00125-008-0954-7 · Cited by 143
Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis
De Groot, J., Wu, D., Flynn, D., Robertson, D., Grant, G., & Sun, J. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i2.170 · Cited by 77
Preiss, D., Zetterstrand, S., McMurray, J. J. V., Östergren, J., Michelson, E. L., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., Gerstein, H. C., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1709 · Cited by 76
“77) (6), or elevated A1C, a marker of cumulative glucose exposure (7,8); 3) combinations of measures of obesity and dysglycemia (9); and 4) risk scores or questionnaires such as the Cambridge Diabetes Risk Score (10), which combines age, sex, BMI, history of antihypertensive or steroid medication, family history, and…”
Background
Metadata
- Authors
- NORBERG, M., ERIKSSON, J. W., LINDAHL, B., ANDERSSON, C., ROLANDSSON, O., STENLUND, H., & WEINEHALL, L.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2006-07-26
- Volume
- 260
- Issue
- 3
- Pages
- 263-271
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2090742050
- Cited by
- 84
- References
- 10
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.